Browse News
Filter News
Found 136 articles
-
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/10/2024
Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, presented two posters at the 2024 American Association for Cancer Research Annual Meeting, held April 5-10, 2024 in San Diego, Calif.
-
Predicine Announces Collaboration with Apollomics to Develop PredicineCARE™ as a Companion Diagnostic Assay in Lung Cancer
4/5/2024
Predicine, Inc., a leading molecular insights company, announced a collaboration with Apollomics, Inc.
-
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
4/2/2024
Apollomics Inc. today announced poster presentations on vebreltinib (APL-101) at the 2024 American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, Calif.
-
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
3/28/2024
Apollomics Inc. announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline.
-
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
3/26/2024
Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets.
-
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
3/4/2024
Apollomics Inc., a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics.
-
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2/7/2024
Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET.
-
Apollo Medical Holdings, Inc. Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
1/24/2024
Apollo Medical Holdings, Inc. today announced that effective on January 23, 2024, the Compensation Committee of ApolloMed's Board of Directors (the "Committee") granted 85,130 shares of time-based restricted common stock and 65,265 shares of performance-based restricted common stock to Dinesh M. Kumar, M.D., the Company's newly-hired Chief Medical Officer, under the Apollo Medical Holdings, Inc. Employment Inducement Award Plan (the "Inducement Plan").
-
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement
1/19/2024
Apollomics Inc. announced that on January 16, 2024, it received a notification from The Nasdaq Stock Market LLC stating that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s Class A ordinary shares, par value $0.0001 per share, was below $1.00 per share for 30 consecutive business days.
-
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
1/17/2024
Apollomics Inc. (“Apollomics” or the “Company”) today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET.
-
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
1/3/2024
Apollomics Inc. announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan, an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia.
-
Apollomics to Present at the 2024 Biotech Showcase
1/2/2024
Apollomics Inc. announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on Monday, January 8, 2024 at 10:30 a.m. PT at the Hilton San Francisco Union Square in San Francisco, Calif.
-
Apollo Medical Holdings, Inc. Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - December 18, 2023
12/18/2023
Apollo Medical Holdings, Inc. announced that effective on December 15, 2023, the Compensation Committee of ApolloMed's Board of Directors granted a total of 38,779 shares of restricted common stock to eight newly-hired non-executive employees, under the Apollo Medical Holdings, Inc. Employment Inducement Award Plan.
-
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
12/4/2023
Apollomics Inc. today announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC), that was held December 1-3, 2023, in Chicago, Illinois.
-
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
11/29/2023
Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Co-Founder and Chief Executive Officer of Apollomics and Sanjeev Redkar, Ph.D., Co-Founder and President, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:30 a.m. ET.
-
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
11/28/2023
Apollomics Inc. (Nasdaq: APLM) (the “Company”) today announced a poster presentation of clinical results for vebreltinib in the treatment of NSCLC with MET exon 14 skipping mutation with or without concurrent MET amplification at the 2023 IASLC North America Conference on Lung Cancer (NACLC), being held on December 1 through 3, 2023 in Chicago, Illinois.
-
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
11/16/2023
Apollomics Inc. today announced that its partner in China, Avistone Biotechnology Co. Ltd., received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).
-
Apollo Medical Holdings, Inc. to Participate in Upcoming November 2023 Investor Conference
11/13/2023
Apollo Medical Holdings, Inc. announced that leadership is participating in the BTIG Digital Health Forum, being held virtually, on Monday, November 20, 2023, including a panel discussion with Brandon Sim, Co-Chief Executive Officer, at 12:00 p.m. PT/3:00 p.m. ET.
-
Apollo Medical Holdings, Inc. Announces Definitive Agreement to Acquire Assets of Community Family Care Medical Group IPA, Inc. and Health Plan
11/7/2023
Apollo Medical Holdings, Inc. announced that it and its affiliated professional entity have entered into a definitive agreement to acquire assets relating to Community Family Care Medical Group IPA, Inc., including the CFC independent physician association, the CFC Health Plan and CFC's management services organization entities.
-
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
10/31/2023
Apollomics Inc. today announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in patients with non-small cell lung cancer (NSCLC) and other solid tumors.